FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 323:17-21 July 5, 1990 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Despite a success rate of more than 90 percent in inducing remission in children with acute lymphocytic leukemia, 30 to 40 percent of such children relapse. Maintenance therapy during remission usually includes oral mercaptopurine and methotrexate. Recently, wide variability in the bioavailability of oral mercaptopurine has been demonstrated, and there is concern that this may affect the risk of relapse. METHODS. To investigate whether lower systemic exposure to mercaptopurine may increase the risk of relapse in acute lymphocytic leukemia, we prospectively studied 23 children receiving maintenance therapy. On the basis of disease features, 11 were classified as being at low risk of relapse, and 12 at standard risk. Those who relapsed (n = 10) did not differ from those who did not in their mean age, hemoglobin level, mean daily dose of mercaptopurine and weekly dose of methotrexate, or the total number of days during which mercaptopurine and methotrexate therapy was interrupted. RESULTS. There was a significant difference in the mean (+/- SEM) area under the mercaptopurine concentration-time curve achieved by a dose of 1 mg of mercaptopurine per square meter of body-surface area: 1636 +/- 197 nmol per liter x minutes in those who relapsed, as compared with 2424 +/- 177 nmol per liter x minutes in those who did not (P less than 0.005). This caused a significantly lower total daily systemic exposure to mercaptopurine in those who relapsed (104,043 +/- 12,812 nmol per liter x minutes) than in those who did not (168,862 +/- 18,830 nmol per liter x minutes) (P less than 0.005). An identical tendency prevailed when patients at low risk and patients at standard risk were analyzed separately. Kaplan-Meier analysis revealed that children in whom an area under the curve of less than 1971 nmol per liter x minutes was achieved by a dose of 1 mg of mercaptopurine per square meter had a significantly poorer prognosis than those with larger areas under the curve (P less than 0.01). Similarly, those with a total daily systemic exposure of more than 137,970 nmol per liter x minutes had a significantly better prognosis than those with a lower exposure (P less than 0.005). CONCLUSIONS. Low systemic exposure to oral mercaptopurine during maintenance therapy for acute lymphocytic leukemia in childhood adversely affects prognosis. Children should be studied at the beginning of maintenance therapy to establish the pharmacokinetics of mercaptopurine, and the dose should be tailored to achieve an appropriate systemic exposure.

Source Information

Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada.

This article has been cited by other articles:

• Malbasa, T., Kodish, E., Santacroce, S. J. (2007). Adolescent Adherence to Oral Therapy for Leukemia: A Focus Group Study. Journal of Pediatric Oncology Nursing 24: 139-151 [Abstract]  
• Clunie, G. P. R., Lennard, L. (2004). Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 43: 13-18 [Abstract] [Full Text]  
• Bhatia, S., Sather, H. N., Heerema, N. A., Trigg, M. E., Gaynon, P. S., Robison, L. L. (2002). Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 100: 1957-1964 [Abstract] [Full Text]  
• Dervieux, T., Chu, Y., Su, Y., Pui, C.-H., Evans, W. E., Relling, M. V. (2002). HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy. Clin. Chem. 48: 61-68 [Abstract] [Full Text]  
• Friedmann, A. M., Weinstein, H. J. (2000). The Role of Prognostic Features in the Treatment of Childhood Acute Lymphoblastic Leukemia. The Oncologist 5: 321-328 [Abstract] [Full Text]  
• Mahoney, D. H. Jr, Shuster, J. J., Nitschke, R., Lauer, S., Steuber, C. P., Camitta, B. (2000). Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study. JCO 18: 1285-1294 [Abstract] [Full Text]  
• Balis, F. M., Adamson, P. C. (1999). Application of Pharmacogenetics to Optimization of Mercaptopurine Dosing. JNCI J Natl Cancer Inst 91: 1983-1985 [Full Text]  
• Balis, F. M., Holcenberg, J. S., Poplack, D. G., Ge, J., Sather, H. N., Murphy, R. F., Ames, M. M., Waskerwitz, M. J., Tubergen, D. G., Zimm, S., Gilchrist, G. S., Bleyer, W. A. (1998). Pharmacokinetics and Pharmacodynamics of Oral Methotrexate and Mercaptopurine in Children With Lower Risk Acute Lymphoblastic Leukemia: A Joint Children's Cancer Group and Pediatric Oncology Branch Study. Blood 92: 3569-3577 [Abstract] [Full Text]  
• Hon, Y. Y., Evans, W. E. (1998). Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin. Chem. 44: 388-400 [Abstract] [Full Text]